Is DiaSorin a public company?
Yes, DiaSorin S.p.A. is a public company. Its shares are listed and traded on the Borsa Italiana (the Italian Stock Exchange) under the ticker symbol "DIA." As a publicly traded entity, it is part of the FTSE MIB index, which tracks the most significant companies listed on the Italian exchange. Since its management buyout and independence in 2000, the company has operated under the transparency and reporting requirements expected of a major multinational public corporation, providing shareholders with regular financial disclosures regarding its immunodiagnostics, molecular diagnostics, and life sciences business operations.
Related FAQs
Yes, DiaSorin officially acquired Luminex Corporation in 2021 for approximately $1.8 billion.
"DIC" can refer to multiple entities depending on the sector.
Yes, Diasorin is a global leader in the biotechnology and diagnostic sector. The company specializes in the development, production, and commercialization of diagnostic tests for a wide range of clinical conditions.
Market analysts are currently divided on Diasorin (DSR), with a consensus that leans toward "Hold" rather than a definitive buy or sell.
DiaSorin is primarily classified as an in vitro diagnostics (IVD) company, which places it within the broader medical equipment and biotechnology sectors.
Yes, DiaSorin is an Italian multinational company. It is headquartered in Saluggia, in the Piedmont region of Italy.